Product Description
a long-acting, recombinant GLP-1 analogue for the treatment of certain diseases, including conditions related to sarcopenia. PB1023 was created as a genetic fusion protein utilizing PhaseBioÕs proprietary elastin-like polypeptide (ÒELPÓ) technology platform. (Sourced from: https://investors.phasebio.com/news-releases/news-release-details/phasebio-announces-global-license-pb1023-treatment-sarcopenia)
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: PhaseBio
Company Location: MALVERN PA 19355
Company CEO: Jonathan P. Mow
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Type 2 Diabetes
Phase 1: Type 2 Diabetes|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
PB1023-PT-CL-0004 | P2 |
Completed |
Type 2 Diabetes |
2013-07-01 |
|
PB1023-PT-CL-0003 | P1 |
Completed |
Type 2 Diabetes|Kidney Diseases |
2012-10-01 |
|
PB1023-PT-CL-0002 | P1 |
Completed |
Type 2 Diabetes |
2012-09-01 |
|
PB1023-PT-CL-0001 | P2 |
Completed |
Type 2 Diabetes |
2011-11-01 |